Independent Pharmacy Valuation Guide: What Your Pharmacy Is Worth in 2026

If you own an independent pharmacy doing between $1M and $10M in revenue, your business is likely worth somewhere between 3x and 6x EBITDA — but where you land in that range can mean a $400,000 difference on the same dispensary. The number isn't arbitrary. Buyers price pharmacies on a specific set of metrics: weekly Rx volume, payer mix, owner dependency, and how transferable your patient relationships are. This guide walks through exactly how the math works, what shifts your multiple up or down, and includes a full worked example so you can estimate your own pharmacy's value before you ever talk to a buyer.

Who Is Buying Independent Pharmacies Right Now

The buyer pool for independent pharmacies in 2026 is more active than most owners realize, but each buyer type values your pharmacy differently.

Banner affiliates (Pharmasave, PharmaChoice, Rexall affiliates) are the most common acquirers in the $1M–$5M revenue range. They typically pay 3.5x–4.5x EBITDA and want pharmacies that fit their existing geographic footprint. Expect them to push for an asset sale and a 6–12 month transition.

PE-backed consolidators are paying the highest multiples — 5x to 6x EBITDA — but they only look at pharmacies doing $400K+ EBITDA with strong dispensary economics. They want platforms or tuck-ins, and they care about scalable systems, not your front-end candy aisle.

Independent pharmacist operators using SBA financing (or CSBFP in Canada) typically pay 3x–4x EBITDA. They're financing-constrained, so deals are smaller and slower, but they often agree to better non-financial terms (keeping staff, brand, location).

Regional pharmacy groups — small chains of 3–15 stores — pay 4x–5x for pharmacies that round out a regional cluster. They're strategic buyers and will pay up for compounding capability or specialty Rx volume they don't already have.

Strategic buyers seeking specific capability (sterile compounding, long-term care contracts, methadone licensing) can pay above market for the right asset, sometimes 6x+ when the capability is hard to replicate.

What Buyers Pay: EBITDA Multiples Explained

Independent pharmacies trade in a 3x–6x EBITDA range, with the spread driven almost entirely by Rx volume, payer mix, and transferability. Here's how the tiers break down:

Tier 1 — Premium (5x–6x EBITDA)

• 2,500+ Rxs/week and growing year-over-year
• Sterile or specialty compounding capability
• Owner works ON not IN the business; licensed pharmacist staff in place
• Less than 50% public drug plan revenue
• 7+ year lease with renewal options
• EBITDA above $500K

Tier 2 — Solid (4x–5x EBITDA)

• 1,500–2,500 Rxs/week, stable
• Some non-sterile compounding
• Owner-pharmacist but with at least one full-time staff pharmacist
• 50%–65% public drug plan mix
• 5+ year lease secured
• EBITDA $250K–$500K

Tier 3 — Average (3x–4x EBITDA)

• 800–1,500 Rxs/week, flat or declining
• Dispensing only, no compounding
• Owner-pharmacist with no licensed backup
• 65%+ public drug plan dependency
• Short lease (under 3 years) or month-to-month
• EBITDA under $250K

Tier 4 — Distressed (below 3x or asset-only sale)

• Declining Rx count, losing patients to nearby chain
• Owner is the only pharmacist and is exiting due to retirement/health
• Lease expiring with no renewal
• These often sell as a prescription file transfer ($15–$40 per active Rx file) rather than a going-concern business

How to Calculate Your Pharmacy's Valuation: A Worked Example

Pharmacy valuation follows a three-step formula: (1) calculate true EBITDA, (2) apply the correct multiple, (3) adjust for working capital and inventory.

Step 1: Calculate Adjusted EBITDA

Start with your net income from the tax return, then add back:

• Interest expense
• Taxes
• Depreciation and amortization
• Owner's salary above market replacement (a staff pharmacist costs $140K–$160K fully loaded; anything you pay yourself above that is an add-back)
• One-time expenses (legal fees, renovation, COVID-era costs)
• Personal expenses run through the business (vehicle, travel, family on payroll)

Step 2: Apply the Multiple

Use the tier framework above honestly. Most owners overestimate their tier by one full level.

Step 3: Worked Example — A Real Pharmacy

Let's value a hypothetical independent pharmacy:

• Revenue: $3.2M ($2.6M dispensary, $600K front-end)
• Rx volume: 1,800/week, stable
• Payer mix: 58% public drug plan, 32% private, 10% cash
• Net income on tax return: $185,000
• Owner pays himself: $220,000 as the lead pharmacist
• Market replacement pharmacist cost: $155,000
• Add-backs: $65,000 owner comp above market + $18,000 depreciation + $12,000 one-time renovation + $8,000 personal vehicle = $103,000

Adjusted EBITDA = $185,000 + $103,000 = $288,000

This pharmacy fits solidly in Tier 2 (stable 1,800 Rxs/week, owner-pharmacist with one staff pharmacist, manageable public plan mix, 6 years left on lease). Apply a 4.5x multiple.

Enterprise value = $288,000 × 4.5 = $1,296,000

Step 4: Add Inventory and Adjust for Working Capital

Pharmacy deals typically include inventory at cost on top of the enterprise value. If this pharmacy carries $180,000 in saleable inventory at cost on closing day, the buyer pays:

$1,296,000 + $180,000 inventory = $1,476,000 total purchase price

If the same pharmacy had a staff pharmacist running the dispensary, compounding revenue of $200K/year, and 8 years left on the lease, the multiple would push to 5.25x and the enterprise value would jump to roughly $1,512,000 — a $216,000 swing on the same EBITDA.

What Pushes Your Multiple Up

Six factors consistently drive multiples toward the top of the range:

• Rx volume above 2,000/week with year-over-year growth. Volume signals patient stickiness and gives the buyer confidence the dispensary isn't bleeding. Growing volume can add 0.5x–1.0x to the multiple alone.

• Compounding capability, especially sterile or hormone replacement. Non-sterile compounding adds modestly; sterile compounding (with the facility, certification, and trained staff) can push you a full tier higher because it's expensive and slow for a buyer to replicate.

• Licensed pharmacist staff who aren't you. A staff pharmacist with 3+ years of tenure and patient relationships means the dispensary keeps operating the day after closing. This is the single biggest lever most owners can pull.

• Diversified payer mix with public plan dependency under 50%. Private insurance and cash pay carry better margins and aren't exposed to provincial/state reimbursement cuts. Buyers heavily discount pharmacies above 65% public plan exposure.

• Long lease in a stable location. 7+ years remaining (including options) with rent under 4% of revenue is a green flag. Buyers won't pay premium multiples on a pharmacy that might lose its location in 18 months.

• Documented patient loyalty. Average patient relationship of 5+ years, low Rx transfer-out rate, and visible community ties (local employer relationships, long-term care contracts) all matter.

What Pulls Your Multiple Down

Be honest about these — buyers will find them in due diligence anyway:

• You are the only licensed pharmacist. This is the single most common multiple-killer. If the dispensary can't legally operate without you on day one post-close, buyers either discount heavily (1x–1.5x off the multiple) or require a 12–24 month earnout tied to your continued employment.

• Public drug plan revenue above 65%. Ongoing pharmacy reimbursement pressure means buyers price in margin compression. Heavy public plan pharmacies often cap at 3.5x even with good volume.

• Declining Rx count. Even a 5% year-over-year decline triggers buyer questions. A 10%+ decline often takes you out of going-concern pricing entirely and into a prescription file sale.

• Short or unstable lease. Under 3 years remaining without a renewal option will cost you 0.5x–1.0x on the multiple. A landlord who's already signaled they want the space back can sink the deal entirely.

• Heavy front-end retail with weak dispensary. Buyers pay for Rx volume, not Coke and chips. If 40%+ of your revenue is front-end with thin margins, expect the front-end to be valued at 2x–3x EBITDA while the dispensary carries the multiple.

The Owner Dependency Problem

This is the issue that costs independent pharmacy sellers more money than any other, and it's specific to how pharmacies operate legally and relationally.

In most jurisdictions, a pharmacy cannot dispense without a licensed pharmacist on premises. If you are that pharmacist — and you're also the relationship every long-term patient trusts — then on the day you walk out, the buyer faces two simultaneous risks: (1) operational shutdown if they can't immediately staff a replacement pharmacist, and (2) patient flight as your regulars transfer their files to a competing pharmacy.

Buyers price this risk aggressively. An owner-only pharmacy typically sees:

• Multiple discounted by 1.0x–1.5x versus a comparable pharmacy with staff pharmacist coverage
• 30%–50% of the purchase price held back in an earnout tied to Rx retention over 12–24 months
• A required transition period of 6–18 months where you stay on as employed pharmacist

The fix takes 18–24 months and is worth doing before you list: hire a staff pharmacist, gradually transition patient relationships (introduce them, have the staff pharmacist counsel them, put their name on refill calls), and document that the dispensary runs without you for full weeks at a time. A pharmacy where the owner takes a four-week vacation without operational issues will defend its multiple in due diligence. One where the owner hasn't taken more than a long weekend in five years will not.

What Buyers Look At in Due Diligence

Once you're under LOI, expect requests for all of the following. Have these ready before you go to market — gaps slow deals and create price re-trades:

• 3 years of dispensary software reports showing Rx counts by month, top 50 drugs, payer mix breakdown, and average Rx margin
• 3 years of tax returns and financial statements, plus year-to-date financials
• Patient file aging report — how many active patients (filled an Rx in last 12 months), how many dormant, average tenure
• Top patient concentration — what % of revenue comes from your top 10, 25, and 100 patients
• Long-term care or institutional contracts — copies, terms, renewal dates
• Lease agreement with all amendments and a landlord estoppel certificate
• Pharmacist licensing and employment records — current, no disciplinary issues, employment contracts
• Compounding logs, USP 795/797 compliance records if applicable, and provincial/state pharmacy board inspection reports
• Inventory listing at cost, separated by Rx inventory, controlled substances, and front-end
• Wholesaler purchasing data (typically 24 months from McKesson, Kohl & Frisch, or equivalent) — buyers use this to verify revenue

Common Mistakes Sellers Make

Five mistakes show up in nearly every independent pharmacy deal that underperforms:

• Listing too late, after Rx volume has already started declining. Once you're in decline, every month costs you multiple. The right time to sell is 12–18 months into a stable or growing trend, not after retirement burnout has set in and you've stopped chasing new patients.

• Not hiring a staff pharmacist before listing. Owners convince themselves the buyer will "figure out" pharmacist coverage. The buyer's response is either a lower price or a longer earnout. Hiring a staff pharmacist 18 months before sale typically returns 4x–6x the salary cost in increased valuation.

• Overstating add-backs. Padding EBITDA with questionable add-backs (your spouse's part-time bookkeeper salary, the family trip you called a conference) gets caught in QofE analysis and damages buyer trust. Stick to defensible add-backs.

• Ignoring the lease until the last minute. If your lease expires in 18 months and you haven't renewed, buyers assume the worst. Negotiate a lease extension before going to market — even if it's slightly above market rent, a secured 7-year term is worth far more in valuation than the rent premium costs.

• Telling staff and patients too early. Patient anxiety drives Rx transfers, and Rx transfers during a sale process can collapse the deal. Most successful deals keep the transaction confidential until after closing or the final transition meeting.

Frequently Asked Questions

Q: How long does it take to sell an independent pharmacy?

A: From listing to close, typical timelines are 6–12 months. Add 12–24 months if you need to address owner-dependency issues (hiring a staff pharmacist) before listing. Banner affiliate buyers often close faster (4–6 months) than PE consolidators (8–14 months).

Q: What is a good EBITDA multiple for an independent pharmacy?

A: Independent pharmacies trade between 3x and 6x EBITDA. A good multiple is anything above 4.5x — to get there, you typically need stable Rx volume above 1,500/week, a staff pharmacist, and a secured lease. Premium multiples (5x–6x) require compounding capability or scale above $500K EBITDA.

Q: Is my prescription file worth anything separately from the business?

A: Yes. Active prescription files trade at $15–$40 per file in a file-only transfer, depending on patient tenure, payer mix, and geographic competition. This is the floor value — most owners get far more by selling as a going concern, but the file value is what you fall back to if the business can't sell intact.

Q: Do I need to stay after selling my pharmacy?

A: Almost always, yes. Expect 6–18 months of transition as a staff pharmacist, often required by the buyer's financing. If you're the only licensed pharmacist, the transition period and the earnout component tied to it will both be longer.

Q: How is inventory handled in a pharmacy sale?

A: Standard practice is that inventory is paid for at cost on top of the enterprise value, counted on closing day. A $1.3M enterprise value pharmacy with $180K of saleable inventory results in a $1.48M total purchase price. Expired or near-expired inventory is excluded from the count.

Q: Should I use a broker or M&A advisor to sell my pharmacy?

A: For pharmacies under $200K EBITDA, a broker may be sufficient. Above that, an M&A advisor with healthcare experience typically returns several multiples of their fee by running a competitive process and bringing PE and consolidator buyers most owners can't reach directly. A marketplace approach (like Serava) sits in between — broader buyer reach without traditional broker fees.

Q: What happens to my staff when I sell?

A: In most banner affiliate and consolidator deals, staff are retained — buyers want continuity, especially with licensed pharmacists and senior technicians. Negotiate staff continuity into the LOI explicitly. In independent operator deals, staff retention is usually offered but not always required.

Frequently Asked Questions

How do I value an independent pharmacy business?

Independent pharmacies are valued at 3x–6x adjusted EBITDA, plus inventory at cost. Start by calculating adjusted EBITDA (net income plus interest, taxes, depreciation, owner compensation above market, and one-time expenses), then apply a multiple based on Rx volume, payer mix, lease term, and pharmacist staffing.

What EBITDA multiple do independent pharmacies sell for in 2026?

Independent pharmacies trade between 3x and 6x EBITDA in 2026. The median is around 4x–4.5x. Premium multiples of 5x–6x go to pharmacies with 2,000+ Rxs/week, compounding capability, staff pharmacist coverage, and diversified payer mix.

How much is a pharmacy worth per prescription?

In a going-concern sale, pharmacies are valued on EBITDA, not per Rx. But as a rough benchmark, a healthy independent pharmacy is worth roughly $400–$900 per weekly Rx in enterprise value. In a prescription-file-only sale, active patient files transfer for $15–$40 per file.

Do I need a licensed pharmacist on staff to sell my pharmacy?

Not legally required, but operationally critical. If you are the only licensed pharmacist, expect your multiple to be discounted by 1.0x–1.5x and 30%–50% of the purchase price held back in an earnout. Hiring a staff pharmacist 18 months before listing is the single highest-return preparation step.

What documents do I need to sell an independent pharmacy?

Three years of tax returns and financial statements, dispensary software reports showing Rx counts and payer mix, patient file aging, lease agreement, pharmacist licensing records, compounding compliance documentation, wholesaler purchase history, and an inventory listing at cost. Having these ready before listing significantly accelerates the deal.

How long does it take to sell an independent pharmacy?

Six to twelve months from listing to close is typical. Banner affiliate buyers can move faster (4–6 months); PE consolidators take 8–14 months due to deeper diligence. Add 12–24 months upfront if you need to hire staff pharmacists or fix lease issues before going to market.

Should I sell to a banner chain or an independent buyer?

Banner affiliates and consolidators typically pay higher multiples (4.5x–6x) and close faster, but may rebrand and change operations. Independent pharmacist buyers pay less (3x–4x) but often preserve the brand, staff, and community feel. The right choice depends on whether you're optimizing for price or legacy.